Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.

Ruxolitinib, a Janus kinase (JAK) inhibitor, has been used orally for over a decade in the treatment of myelofibrosis. The immunosuppressive and anti-inflammatory properties of ruxolitinib have made it an attractive treatment option for several dermatologic conditions, such as atopic dermatitis, psoriasis, alopecia areata, and vitiligo. In October 2021, US Food and Drug Administration approved ruxolitinib as the first topical JAK inhibitor for treating atopic dermatitis. Recent studies have demonstrated its efficacy for both visible manifestations and itch of atopic dermatitis. These results indicate that topical ruxolitinib could be used as a long-term glucocorticoid for treating atopic dermatitis. While more studies are required to compare it to classic topical treatments of atopic dermatitis, topical ruxolitinib has a promising future in the field of dermatology. (SKINmed. 2023;21:40-43).